Oncimmune Holdings PLC (LON:ONC) has noted that researchers driving innovation at the cancer diagnostic group have contributed "world-class science” to the field of rheumatoid arthritis (RA) and it’s early detection.
That’s the opinion of Oncimmune’s chief executive, Dr Adam Hill, whose ImmunoINSIGHTS team was integral to a paper published in the journal ‘Arthritis Research & Therapy’.
Led by Oncimmune's Dr Petra Buddle and Dr Hans-Dieter Zucht, a study was set up to assess the diagnostic potential of IgG antibodies in early RA. It did so by assessing 411 patients enrolled in Germany.
The scientists concluded that the autoantibody, cTRA2B-IgG, had the potential to improve diagnosis of early-stage rheumatoid arthritis.
“RA is insidious in onset, often resulting in a diagnosis later in the evolution of the disease; clearly, candidate biomarkers able to identify the disease earlier in the majority of sufferers presents a near term opportunity to dramatically improve outcomes,” said CEO Hill in a statement.
“Whilst we remain steadfast in our commitment to cancer patients - supporting the clinical understanding of autoimmune disease biomarkers better enables us to predict side effects in cancer patients treated with immune modulating drugs - the potential to work with biopharma in autoimmune disease is also a possibility," he added.
More details on the paper, 'Profiling IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicentre national cohort of early arthritis in Germany', can be accessed by clicking this link.